pneumococcal cervical cancer ovarian cancer Hepatitis C cardiovascular disease anxiety ≥ 140 mg/dL diabetes 65 y.o. Hepatitis B 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors q1-2y mammogram based on life expectancy / health status 60 y.o. statin q1y < 60 y.o. tamoxifen tobacco use 50 y.o. ≥ 126 mg/dL community- dwelling, postmenopausal women women age 55- 64 y.o. 3% 75 y.o. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor 40-70 y.o., ASCVD ≥ 10%, low bleeding risk q3y 52 y.o. q1y mammogram ≥ 200 mg/dL HIV aspirin depression aromatase inhibitors ≤ q2y dyslipidemia q5y PREVENT equation ≥ 6.5% breast cancer hormone therapy Tyrer- Cuzick model ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors 40-59 y.o., ASCVD ≥ 10%, low bleeding risk dementia ≥ 100 mg/dL lung cancer ≥ 5.7% 2 doses, 2-6 months apart Gail model multidose initial series, then 1 dose at 2-6 months insufficient evidence for screening 40 y.o. 1 dose; 2 doses (2-6 months apart) if immunocomp ≥ 20% herpes zoster Timed up and go test 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor Fracture Risk Assessment Tool raloxifene overweight / obesity hypertension colorectal cancer q2y q15y pneumococcal cervical cancer ovarian cancer Hepatitis C cardiovascular disease anxiety ≥ 140 mg/dL diabetes 65 y.o. Hepatitis B 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors q1-2y mammogram based on life expectancy / health status 60 y.o. statin q1y < 60 y.o. tamoxifen tobacco use 50 y.o. ≥ 126 mg/dL community- dwelling, postmenopausal women women age 55- 64 y.o. 3% 75 y.o. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor 40-70 y.o., ASCVD ≥ 10%, low bleeding risk q3y 52 y.o. q1y mammogram ≥ 200 mg/dL HIV aspirin depression aromatase inhibitors ≤ q2y dyslipidemia q5y PREVENT equation ≥ 6.5% breast cancer hormone therapy Tyrer- Cuzick model ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors 40-59 y.o., ASCVD ≥ 10%, low bleeding risk dementia ≥ 100 mg/dL lung cancer ≥ 5.7% 2 doses, 2-6 months apart Gail model multidose initial series, then 1 dose at 2-6 months insufficient evidence for screening 40 y.o. 1 dose; 2 doses (2-6 months apart) if immunocomp ≥ 20% herpes zoster Timed up and go test 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor Fracture Risk Assessment Tool raloxifene overweight / obesity hypertension colorectal cancer q2y q15y
(Print)
pneumococcal
cervical cancer
ovarian cancer
Hepatitis C
cardiovascular disease
anxiety
≥ 140 mg/dL
diabetes
65 y.o.
Hepatitis B
40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
q1-2y mammogram based on life expectancy / health status
60 y.o.
statin
q1y
< 60 y.o.
tamoxifen
tobacco use
50 y.o.
≥ 126 mg/dL
community-dwelling, postmenopausal women
women age 55-64 y.o.
3%
75 y.o.
40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
40-70 y.o., ASCVD ≥ 10%, low bleeding risk
q3y
52 y.o.
q1y mammogram
≥ 200 mg/dL
HIV
aspirin
depression
aromatase inhibitors
≤ q2y
dyslipidemia
q5y
PREVENT equation
≥ 6.5%
breast cancer
hormone therapy
Tyrer-Cuzick model
≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
40-59 y.o., ASCVD ≥ 10%, low bleeding risk
dementia
≥ 100 mg/dL
lung cancer
≥ 5.7%
2 doses, 2-6 months apart
Gail model
multidose initial series, then 1 dose at 2-6 months
insufficient evidence for screening
40 y.o.
1 dose; 2 doses (2-6 months apart) if immunocomp
≥ 20%
herpes zoster
Timed up and go test
40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
Fracture Risk Assessment Tool
raloxifene
overweight / obesity
hypertension
colorectal cancer
q2y
q15y
